Relay Therapeutics (RLAY) logo

Relay Therapeutics (RLAY) stock

Precision medicine , market cap $3.5B

After-hours Fri
$16.19
+0.46%

Close $16.12 +1.32%

Why RLAY fell on Nov 5

Down 5.7% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6.3%.

  • Its Nov 4 results: net loss widened to $81.7M, from $74.1M a year before; research and development expenses were $77.1M, from $68.3M. It fell 6% on Nov 5.

Sources: Price history, Nov 5, 2026; Company release, Nov 4, 2026

Tell me next time RLAY moves

Free account, no card. An optional alert when RLAY moves or its score changes.Pro, $1 for a first month. An optional alert when RLAY moves or its score changes.Pro, 7 days free with a card. An optional alert when RLAY moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on RLAY →2 more reasons why RLAY fell on Nov 5, from its filings, with the other side, how the business stands, the timeline, and its peers, for Pro members.

Why RLAY still beats the market over a year

Up 153% over the year to Nov 20 while the S&P 500 rose 7%; down 6% on Nov 5.

1 reason, from its filings, with the timeline and its peers, for Pro members.

Quality Score
4
Below Average
In its industry
#66of 273
Checks firing
3of 14
Choppy
From 52-week high
-24.2%
under its best in a year

RLAY's Quality Score rose 3 points on Fri, Nov 20, to 4. More shares traded than usual (3 chart checks started).

Follow RLAY's trial news. Pro members can get an alert when Relay Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when RLAY files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextMid-2027“Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027”Trial start · SEC filing · Nov 4

Key facts on RLAY

Key facts on RLAY
Since its 2022 highDown 54% while sales grew 242%
Latest filing8-K, Nov 4 Reported its quarterly results

RLAY catalysts

Coming up

After its last 4 reports it closed +1.4% on average, higher 2 of 4 times.

5 past catalysts since 2021, with sizes and sources, for Pro members.

What's next for RLAY, and how long its cash lasts

Next step the company has named

Mid-2027“Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027”Trial start · SEC filing · Nov 4

What it means: when a trial begins, or reaches the stage the company named.

A trial underway
ReDiscover-2Phase 3 · Recruiting · 540 people · main data estimated Apr 30, 2028 · NCT06982521

3 more trials, 30 filings, for Pro members.

Cash runway

The company says its cash lasts into 2029 (8-K, Nov 4).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

CEO Sanjiv Patel sold 48,202 shares on Nov 19, under a planned sale. 32 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Sanjiv Patel’s 20 filings and quotes.

Get an alert when RLAY files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why RLAY scores 4

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

  • +3Chart checks 3 of 14 firing right now, one point each
  • +2Long-term trend above a rising 200-⁠day average
  • Run-up adds
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on RLAY and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:34 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How RLAY ranks in Biotech

RLAY is #66 of 273 by Quality Score.

How RLAY ranks in Biotech
RankStockQuality Score
66Relay Therapeutics (RLAY) logoRLAYRelay Therapeutics4

Share count against a year before: RLAY +27%, BEAM +2.1%, CRSP +6%, RVMD +14%.

More in Biotech

When does RLAY report earnings, and what happens after?

Expected to report Thu Feb 25, after the close (in 96 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What RLAY reported on Nov 4, 2026

The quarter

A loss of $0.37 a share, from $0.43.

“The increase of $8.8 million was primarily due to increases in costs across ongoing clinical trials, as well as non-recurring costs related to the termination of the company’s operating lease at One Kendall Square, partially offset by the impact from strategic choices made to streamline the research organization prior to 2026.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

RLAY's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increase of $1.0 million was primarily due to non-recurring costs related to the termination of the company’s operating lease at One Kendall Square, as well as increases in other miscellaneous general and administrative costs.”

From its results filing (SEC filing · Nov 4)

1 more sentence, for Pro members.

The numbers

Market value
$3.5B
today
Sales
$10.3M
up 23.9% on the year

Sales fell 29% a year over 5 years, fiscal 2020 to 2025.

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on RLAY: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

+12.0%-0.6%+0.1%-5.7%
Feb 26May 5Aug 6Nov 4
ReportedGapReaction5
days
Nov 4, 2026After close-1.8%-5.7%+9.4%
Aug 6, 2026After close-3.2%+0.1%+0.9%
May 5, 2026After close+0.1%-0.6%-0.5%
Feb 26, 2026After close+5.2%+12.0%+5.2%

RLAY closed higher after 2 of its last 4 reports.

RLAY sales and profit by year

Sales and profit by year

Sales grew in two of the last five years, to $15.4M in 2025. It lost money in each of the six years.

RLAY has 3 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on RLAY, and all 14 on every stock.Get in free →See the top 3 →Start Pro

RLAY RSI on Nov 20: 39.4, below its 50-day, above its 200-day

Not scored

RSI 39.4, MACD below signal, below its 50-day, above its 200-day. Not scored.

The deep dive on RLAY

5 more findings on RLAY, each with its source, for Pro members.

RLAY share count over time

Shares: 27.1% more than a year ago (to Sep 30).

Shares of RLAY outstanding, as filed
Shares
outstanding
As
of
221MOct 30, 2026
219.1MJul 31, 2026
191.6MMay 1, 2026
178.7MFeb 20, 2026
Offerings, shelves, and splits of RLAY, from its filings
From its
filings
Filed
Raised $275M in a sale of shares, about 8% of its market valueMay 21, 2026
Raised $200M in a sale of shares, about 6% of its market valueSep 11, 2024
Registered shares for a later sale (S-3ASR)Aug 6, 2024

RLAY insider trades

4 insiders sold $117M across 7 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellDonald A. Bergstrom$42KPresident, R&Dat $18.62 on Oct 28, filed Oct 30

All 7 insider filings on RLAY from the last six months, for Pro members.

RLAY's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold RLAY?

In ETFs: RLAY is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Relay Therapeutics

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

218 employeesCambridge, MArelaytx.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on RLAY and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn RLAY's score around: 8 things
  • 5 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayOct 30Donald A. Bergstrom sold RLAY$42K at $18.62, filed Oct 30

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: RLAY's Quality Score is 4 (Below Average), #66 of 273 in Biotech. Insiders sold $117M in the last 6 months (Form 4).

What does RLAY's Quality Score say?

RLAY scores 4 today, which Breakaway calls Below Average. It is #66 of 273 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 5.7% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6.3%. Shares: 27.1% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is RLAY's Quality Score?

RLAY scores 4 today, which Breakaway calls Below Average (0 to 5). That is #66 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind RLAY's 4.

Are insiders buying RLAY?

4 insiders sold $117M across 7 filings in the last 6 months. No open-⁠market buys on record. The newest is Donald A. Bergstrom, President, R&D, who sold $42K on Oct 28. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Relay Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.